A Bioequivalence and Food Effect Study in Healthy Subjects Comparing Baricitinib Suspension and Commercial Tablet Formulations

Trial Profile

A Bioequivalence and Food Effect Study in Healthy Subjects Comparing Baricitinib Suspension and Commercial Tablet Formulations

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Atopic dermatitis; Giant cell arteritis; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top